Cambridge Innovation Capital — 2024 Investments
2 investments dated 2024 · listed companies and verified rows first · show all
Bicycle Therapeutics develops precision-guided therapeutics based on its proprietary bicyclic peptide (Bicycle) technology, designed to penetrate deep into tissues and target intractable solid tumor cancers.
BiotechHealthtechCambridge
GREGORY WINTER(Director)KEVIN LEE(Executive Officer, Director)NIGEL CROCKETT(Executive Officer)NICHOLAS KEEN(Executive Officer)SANTIAGO ARROYO(Executive Officer)MICHAEL HANNAY(Executive Officer)
Co-investorsAhren Innovation CapitalAstellas Venture Management LLCLongwood FundSR One Capital ManagementSV Health InvestorsVertex Ventures HC
Epitopea develops off-the-shelf cancer vaccines targeting aberrantly expressed tumor-specific antigens using its proprietary CryptoMap platform.
AI & Machine LearningBiotechHealthtechMontreal, CA
Claude PerreaultPierre Thibault
Co-investorsAdvent Life SciencesCTI Life Sciences Fund L.P.adMare BioInnovationsFonds de solidarité FTQ
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.